A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
